Atara Biotherapeutics, Inc
ATRAAtara Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative cellular immunotherapies for the treatment of life-threatening diseases, including cancers and rare autoimmune disorders. The company leverages allogeneic T-cell technologies to create targeted and durable treatments, aiming to improve patient outcomes in areas with significant unmet medical needs.
Company News
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Atara Biotherapeutics, Inc. for potential securities law violations after the company received a Complete Response Letter from the FDA regarding its Ebvallo drug, leading to a clinical hold and workforce reduction.
FUJIFILM Diosynth Biotechnologies has completed the expansion of its cell therapy manufacturing facility in Thousand Oaks, California, adding two new production suites and increasing cleanroom capacity to support the growing demand for cell therapies.
The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
